PE20140199A1 - 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3 - Google Patents

6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3

Info

Publication number
PE20140199A1
PE20140199A1 PE2013000887A PE2013000887A PE20140199A1 PE 20140199 A1 PE20140199 A1 PE 20140199A1 PE 2013000887 A PE2013000887 A PE 2013000887A PE 2013000887 A PE2013000887 A PE 2013000887A PE 20140199 A1 PE20140199 A1 PE 20140199A1
Authority
PE
Peru
Prior art keywords
methyl
kcnq2
modulators
amino
aliphatic residue
Prior art date
Application number
PE2013000887A
Other languages
English (en)
Inventor
Sven Kuhnert
Gregor Bahrenberg
Achim Kless
Wolfgang Schroder
Simon Lucas
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43447658&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140199(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20140199A1 publication Critical patent/PE20140199A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

REFERIDA A UN DERIVADO DE 6-AMINO-NICOTINAMIDA DE FORMULA (I), DONDE R1 ES UN RESIDUO ALIFATICO C1-C10, UN RESIDUO CILOALIFATICO C3-C10, ENTRE OTROS; R2 ES F, Cl, Br, CN, CF3, ENTRE OTROS; R4 ES UN RESIDUO ALIFATICO C1-C10, UN RESIDUO CILOALIFATICO C3-C10, ENTRE OTROS; R5 ES H O UN RESIDUO ALIFATICO C1-C10; R6 ES UN RESIDUO ALIFATICO C2-C6, UN RESIDUO O-C1-ALIFATICO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N- (3,5-DIFLUORO-FENILO)-METILO-2-ETILOSULFANILO-4-METILO-6 MORFOLINO-4-IL-PIRIDINA-3-AMIDA DE ACIDO CARBOXILICO, 2-ETILOSULFANILO-N-3-FLUOROFENILO-METILO-4-METILO-6-MORFOLINO-4-IL-PIRIDINA-3-AMIDA DE ACIDO CARBOXILICO, N-3,5-DIFLUORO-FENILO-METILO-2-METOXI-4-METILO-6-MORFOLINO-4-IL-PIRIDINA-3-AMIDA DE ACIDO CARBOXILICO, ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES DEL CANAL KCNQ2/3 K+ Y SON UTILES EN EL TRATAMIENTO DEL DOLOR AGUDO, DOLOR CRONICO, DOLOR NEUROPATICO, ENTRE OTROS
PE2013000887A 2010-10-20 2011-10-19 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3 PE20140199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10013811 2010-10-20

Publications (1)

Publication Number Publication Date
PE20140199A1 true PE20140199A1 (es) 2014-02-16

Family

ID=43447658

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000887A PE20140199A1 (es) 2010-10-20 2011-10-19 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3

Country Status (19)

Country Link
US (1) US8552200B2 (es)
EP (2) EP3318556A1 (es)
JP (1) JP5947307B2 (es)
KR (1) KR101820645B1 (es)
CN (1) CN103209962B (es)
AR (1) AR083477A1 (es)
AU (1) AU2011317855B2 (es)
BR (1) BR112013010957A2 (es)
CA (1) CA2815131C (es)
CL (1) CL2013001073A1 (es)
CO (1) CO6690805A2 (es)
EA (1) EA022582B1 (es)
EC (1) ECSP13012573A (es)
ES (1) ES2678899T3 (es)
IL (1) IL225762A (es)
MX (1) MX367623B (es)
NZ (2) NZ610689A (es)
PE (1) PE20140199A1 (es)
WO (1) WO2012052167A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
EP2349279A4 (en) 2008-10-28 2013-12-25 Univ Leland Stanford Junior ALDEHYDE DEHYDROGENASE MODULATORS AND METHOD OF USE THEREOF
US9168259B2 (en) 2010-10-20 2015-10-27 Grünenthal GmbH Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
EP2844645A1 (en) 2012-04-18 2015-03-11 Grünenthal GmbH Substituted 4-aminobenzamides as kcnq2/3 modulators
JP6033403B2 (ja) * 2012-04-18 2016-11-30 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Kcnq2/3調節因子としてのoh含有基を有する置換6−アミノ−ニコチンアミド類
EP2876106A4 (en) * 2012-07-19 2016-03-30 Nippon Soda Co PYRIDINE COMPOUND AND AGRICULTURAL / HORTICULTURAL BACTERICIDE
WO2014056620A1 (en) * 2012-10-11 2014-04-17 Grünenthal GmbH Treatment and/or prophylaxis of tspo mediated diseases and/or disorders
WO2014082737A1 (en) 2012-11-28 2014-06-05 Grunenthal Gmbh Specific carboxamides as kcnq2/3 modulators
EP2925759A1 (en) * 2012-11-28 2015-10-07 Grünenthal GmbH Heteroquinoline-3-carboxamides as kcnq2/3 modulators
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
EP2925316A1 (en) * 2012-11-28 2015-10-07 Grünenthal GmbH Substituted amino-arylcarboxamides as kcnq2/3 modulators
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
US9994641B2 (en) 2013-12-25 2018-06-12 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody that passes through blood-brain barrier
CN111407726A (zh) * 2020-04-13 2020-07-14 牡丹江医学院 一种治疗口腔炎的药物制剂及其制备方法
CN112624966B (zh) * 2020-12-25 2022-12-23 杭州澳赛诺生物科技有限公司 一种2-氨甲基-4-甲基-5-吡啶羧酸的合成方法
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
US11767310B2 (en) 2021-08-10 2023-09-26 Abbvie Inc. Nicotinamide RIPK1 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2230392A1 (de) * 1972-06-22 1974-01-31 Cassella Farbwerke Mainkur Ag Substituierte pyridinverbindungen und verfahren zu ihrer herstellung
DE2513949A1 (de) * 1975-03-29 1976-10-07 Bayer Ag Azofarbstoffe
AU7388701A (en) * 2000-06-29 2002-01-08 Neurosearch As Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
CZ20032233A3 (cs) 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
WO2002072088A2 (en) 2001-02-20 2002-09-19 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
GB0222495D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402357D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
EP2298766B1 (en) * 2005-03-03 2013-09-18 H. Lundbeck A/S Pharmaceutical formulations comrpising a substituted pyridine derivative
WO2007065449A1 (en) * 2005-09-09 2007-06-14 H. Lundbeck A/S Pyrimidine derivatives and their use as kcnq potassium channels openers
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
DE102007044277A1 (de) * 2007-09-17 2009-03-19 Grünenthal GmbH Substituierte Nicotinamid-Verbindungen und deren Verwendung in Arzneimitteln
BRPI0919898A2 (pt) 2008-10-24 2016-02-16 Gruenenthal Gmbh 4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3
WO2010094644A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
TW201038565A (en) * 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier

Also Published As

Publication number Publication date
CN103209962A (zh) 2013-07-17
AU2011317855A1 (en) 2013-05-02
IL225762A (en) 2017-06-29
JP2014510696A (ja) 2014-05-01
CA2815131C (en) 2020-06-09
AR083477A1 (es) 2013-02-27
BR112013010957A2 (pt) 2016-08-30
US8552200B2 (en) 2013-10-08
EA201300471A1 (ru) 2014-01-30
ES2678899T3 (es) 2018-08-20
NZ628871A (en) 2015-07-31
MX367623B (es) 2019-08-29
EP2630123B1 (en) 2017-12-20
EP3318556A1 (en) 2018-05-09
US20120101079A1 (en) 2012-04-26
WO2012052167A1 (en) 2012-04-26
CO6690805A2 (es) 2013-06-17
CL2013001073A1 (es) 2013-10-11
MX2013004329A (es) 2013-04-29
KR101820645B1 (ko) 2018-01-22
EP2630123A1 (en) 2013-08-28
AU2011317855B2 (en) 2015-04-30
NZ610689A (en) 2014-08-29
EA022582B1 (ru) 2016-01-29
KR20140001904A (ko) 2014-01-07
IL225762A0 (en) 2013-06-27
CA2815131A1 (en) 2012-04-26
CN103209962B (zh) 2016-03-02
ECSP13012573A (es) 2013-07-31
JP5947307B2 (ja) 2016-07-06

Similar Documents

Publication Publication Date Title
PE20140199A1 (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3
PE20131379A1 (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores kcnq2/3
PE20142452A1 (es) AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2
PE20120780A1 (es) Nicotinamida sustituida como moduladores kcnq2/3
PE20161243A1 (es) Compuesto heterociclico fusionado
MX2015009591A (es) Amidas como moduladores de canales de sodio.
MA32534B1 (fr) Dérivés de cyclohexylamide et leur utilisation en tant qu'antagonistes des récepteurs de crf-1
PH12015501661B1 (en) Pyridone amides as modulators of sodium channels
MX2015009592A (es) Quinolina y quinazolina amidas como moduladores de canales de sodio.
PE20120790A1 (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
GEP20146125B (en) Aminopyrimidines as syk inhibitors
PE20121335A1 (es) Compuestos derivados de amida como inhibidores de raf cinasas
EA201500652A1 (ru) Дифторметилникотиновые инданилкарбоксамиды
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20150403A1 (es) Pirrol carboxamidas fluorometilo sustituidas
PE20160664A1 (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
MX2011009493A (es) Compuestos para el tratamiento de trastornos metabolicos.
EA201170051A1 (ru) Гетероциклическое соединение и его применение
EA201300442A1 (ru) ПИРРОЛИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ MetAP-2
CO6341581A2 (es) Derivados de heteroarilo como inhibidores de dgat1
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
PE20150709A1 (es) Benzamidas
MX2010009576A (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.

Legal Events

Date Code Title Description
FC Refusal